Topics

FDA fast-tracks psilocybin treatment for major depressive disorder

09:42 EST 25 Nov 2019 | Pharmafile

The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the treatment of major depressive disorder (MDD), with the view of accelerating trials testing its efficacy.

Non-profit research organisation The Usona Institue is examining the antidepressant properties of a single psilocybin dose in treating patients with major depressive disorder.

read more

Original Article: FDA fast-tracks psilocybin treatment for major depressive disorder

NEXT ARTICLE

More From BioPortfolio on "FDA fast-tracks psilocybin treatment for major depressive disorder"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...